Biomedical Engineering Reference
In-Depth Information
25. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al.
Combined salmeterol and fluticasone in the treatment of chronic obstructive
pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456.
26. Barnes PJ. Scientific rationale for combination inhalers with a long-acting
b
2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191.
27. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth factor-bl
inhibits b
2
-adrenoceptor gene transcription. Naunyn Schmiedebergs Arch
Pharmacol 2000; 362:520-525.
28. Ishikawa T, Kume H, Kondo M, Ito Y, Yamaki K, Shimokata K. Inhibitory
effects of interferon-gamma on the heterologous desensitization of beta-
adrenoceptors by transforming growth factor-beta 1 in tracheal smooth
muscle. Clin Exp Allergy 2003; 33:808-815.
29. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS,
et al. Transforming growth factor betal and recruitment of macrophages and
mast cells in airways in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 1998; 158:1951-1957.
30. Mak JCW, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective
effects of a glucocorticoid on down-regulation of pulmonary b
2
-adrenergic
receptors in vivo. J Clin Invest 1995; 96:99-106.
31. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, et al. Inter-
action between glucocorticoids and b2 agonists on bronchial airway smooth
muscle
cells
through synchronised cellular
signalling. Lancet
2002;
360:1293-1299..
32. Pang L, Knox AJ. Synergistic inhibition by
b
2
-agonists and corticosteroids on
tumor necrosis factor-
a
-induced interleukin-8 release from cultured human
airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23:79-85.
33. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflamma-
tory markers in patients with chronic bronchitis. Am J Respir Crit Care
Med 1999; 160:893-898.
34. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes
and prostaglandins in COPD. Thorax 2003; 58:585-588.
35. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene
B
4
receptor BLT
2
. A new therapeutic target in inflammation and immunolo-
gical disorders. J Exp Med 2000; 192:421-432.
36. Silbaugh SA, Stengel PW, Cockerham SL, Froelich LL, Bendele AM, Spaethe
SM, et al. Pharmacologic actions of the second generation leukotriene B
4
receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmiede-
bergs Arch Pharmacol 2000; 361:397-404.
37. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in
acute bacterial exacerbations of chronic bronchitis: the role of leukotriene
B4. Eur Respir J 2000; 15:274-280.
38. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ.
Neutrophil chemotactic activity of sputum from patients with COPD: role
of interleukin 8 and leukotriene B4. Chest 2003; 123:1240-1247.
39. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a
leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122:
289-294.
